RE:RE:ONCY accumulated deficit (Tax losses applied to a buyout) ONCY's estimated accumulated deficit a/o December 31, 2023 is approximately $450 Million,
ONCY's accumulated deficit correlates to research and development expenses are eligible for the Orphan Drug Tax Credit which provides t he sponsor company a 25% tax credit to offset research and development costs (qualified clinical testing). It is intended to incentivize biotechnology companies to invest in the development of treatments that are not otherwise economically viable.
When taking ONCY's accumulated deficit and the company's eligibility for the 25% Orphan Drug Tax Credits, the effective benefit to ONCY shareholders is a minimun of US$5 + US$1.25 = US $6.25 per share.
This minimun US$ 6.25 per share value has still to be reflected in ONCY's current share price.